OptumRx is currently embarking on an initiative to curb the rising tide of opioid abuse across the US. Effective
July 1, 2017, select OptumRx Commercial Clients will align with recent Center for Disease Control (CDC)
guidelines and clinically based prescribing habits on the number of Morphine Milligram Equivalents (MME) a
member can receive at any given time of a Short-Acting Opioid (SAO) medication (brand or generic
product).
*Please see attached PDF for more information.